Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab

Niklas Krupka
Daniel C Baumgart
Division of Gastroenterology and Hepatology, Department of Medicine, Charité Medical School, Humboldt-University of Berlin, Berlin, Germany

Abstract: Crohn’s disease and ulcerative colitis are two chronic inflammatory bowel conditions. Current approved biologic therapies are limited to blocking tumor necrosis factor alpha. Unfortunately, some patients are primary nonresponders, experiencing a loss of response, intolerance, or side effects. This defines an unmet need for novel therapeutic strategies. The rapid recruitment and inappropriate retention of leukocytes is a hallmark of chronic inflammation and a potentially promising therapeutic target. Here we discuss the clinical trial results of vedolizumab (anti-α4β7, LDP-02, MLN-02, and MLN0002) and its impact on future management of inflammatory bowel disease.

Keywords: ulcerative colitis, Crohn’s disease, vedolizumab, MLN0002, MLN-02, LDP-02, anti-α4β7

Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are idiopathic inflammatory bowel diseases (IBD) that mainly affect the gastrointestinal tract but can manifest in the entire human body. From the current understanding, the pathophysiological events in IBD involve a disturbance of the commensal microbiota, an impairment of mucosal defense mechanisms, an increased permeability of the gut’s epithelial layer, and a dysregulation of the innate and adaptive immune system, all of which eventually promote an aberrant immune response against nonpathogenic gut bacteria and subsequent tissue damage.1–4 Genome-wide association studies have shown a wide range of susceptibility loci for CD and UC, with a significant overlap between both diseases; however, the precise interplay of genetic and environmental factors that underlies disease is still unknown.5–7

One of the histopathological hallmarks of CD, UC, and most chronic inflammatory processes in general is a markedly increased number of leukocytes, specifically memory T cells, in affected tissues, which results from increased cell extravasation and/or retention.8,9 Importantly, the transendothelial migration of leukocytes is a highly regulated process that involves numerous leukocyte and endothelial surface molecules.10,11 Specifically, binding of the leukocyte α4β7 integrin to its principal ligand, the mucosal addressin cellular adhesion molecule 1 (MAdCAM-1), which is expressed in high endothelial venules of the gut lamina propria, gut-associated lymphoid tissue, and mesenteric lymph nodes, has been shown to be pivotal in leukocyte homing to the gastrointestinal tract.12–17 In CD and UC, the expression of MAdCAM-1 is highly upregulated in high endothelial venules of inflammatory sites and promotes an increased capacity to bind leukocytes.18,19 This strongly supports relevance of the MAdCAM–1–α4β7 integrin interaction in disease and makes it a promising therapeutic target.
Current targeted therapies for inflammatory bowel disease

Therapies targeting tumor necrosis factor

Prior to the development of targeted therapies, treatment of CD and UC was based on nonselective modulation or suppression of the immune response, which frequently suffered from limited efficacy or severe side effects associated with immunosuppression. More than a decade ago, infliximab (Remicade®; Janssen Biotech Inc.) – a monoclonal antibody targeting tumor necrosis factor (TNF) – was the first biologic therapy to be approved by the US Food and Drug Administration (FDA) for the treatment of CD and later UC. Large clinical trials and a vast amount of clinical data have proven the efficacy of anti-TNF therapy in CD and UC, and its availability has significantly improved treatment of patients with IBD.20–22 In the last few years, other anti-TNF agents such as adalimumab (Humira®; AbbVie), certolizumab (Cimzia®; UCB), and golimumab (Simponi®; MSD) were approved and now allow clinicians to choose among different application routes and intervals (Table 1). Anti-TNF therapy, however, may be associated with a number of serious and potentially life-threatening adverse events, such as malignancies or opportunistic infections.23,24 Moreover, approximately one third of patients are primary nonresponders to anti-TNF therapy, and another 30%–40% of primary responders eventually lose response to treatment or become intolerant.20,25,26 Hence, new therapeutic strategies are urgently needed.

Leukocyte migration inhibitors

Based on the pivotal role of leukocyte migration in the pathogenesis of IBD, much basic and clinical research in recent years has focused on identifying and modifying underlying pathways.9,27 Interestingly, the tissue-specificity of the participating ligands and receptors theoretically allows an organ-selective therapy, compared to the rather radical approach of general immunosuppression or immunomodulation. In 2008, natalizumab (Antegren®; Tysabri®; Biogen Idec Inc.), a humanized monoclonal immunoglobulin G1 antibody against the α4 chains of the α4β7 and α4β1 integrin heterodimers, received FDA approval for the treatment of moderate to severe CD. Natalizumab, which had been used before in the treatment of multiple sclerosis,28–31 inhibits interactions of α4β7 integrin with the vascular cell adhesion molecule-1 (VCAM-1) and of α4β1 integrin with MAdCAM-1, respectively, and thereby impairs leukocyte migration to the central nervous system and the gut.12–17 After significant effects of natalizumab on disease activity in patients with CD were reported in early double-blind, randomized controlled trials,32,33 its efficacy as an induction and maintenance therapy for CD was confirmed in the ENACT (International Efficacy of Natalizumab as Active Crohn’s Therapy) and ENCORE (Efficacy of Natalizumab in Crohn’s Disease Response and Remission) trials.34,35 Studies that evaluate natalizumab in patients with UC are rare; however, results of a small pilot trial with ten patients with active UC suggest a positive efficacy.36 Although an acceptable safety profile

Table 1 Biological therapy for IBD

<table>
<thead>
<tr>
<th>Anti-TNF therapy</th>
<th>Gut-specific integrin antagonists</th>
</tr>
</thead>
<tbody>
<tr>
<td>Available drugs</td>
<td></td>
</tr>
<tr>
<td>Infliximab (Remicade®; Janssen Biotech)</td>
<td>Vedolizumab (Entyvio®; Takeda)</td>
</tr>
<tr>
<td>Adalimumab (Humira®; AbbVie)</td>
<td></td>
</tr>
<tr>
<td>Certolizumab (Cimzia®; UCB)</td>
<td></td>
</tr>
<tr>
<td>Golimumab (Simponi®; MSD)</td>
<td></td>
</tr>
<tr>
<td>FDA approval for IBD</td>
<td>2014</td>
</tr>
<tr>
<td>1998 (infliximab)</td>
<td></td>
</tr>
<tr>
<td>2007 (adalimumab)</td>
<td></td>
</tr>
<tr>
<td>2008 (certolizumab)</td>
<td></td>
</tr>
<tr>
<td>2013 (golimumab)</td>
<td></td>
</tr>
<tr>
<td>Target</td>
<td>α4β1 integrin (cell surface protein on lymphocytes)</td>
</tr>
<tr>
<td>Interval of standard maintenance therapy</td>
<td>4–8 weeks</td>
</tr>
<tr>
<td>8 weeks (infliximab)</td>
<td></td>
</tr>
<tr>
<td>4 weeks (certolizumab, golimumab)</td>
<td></td>
</tr>
<tr>
<td>2 weeks (adalimumab)</td>
<td></td>
</tr>
<tr>
<td>Common adverse events</td>
<td>Infections (especially of the upper-respiratory tract), infusion-related reactions</td>
</tr>
<tr>
<td>Infusions (including reactivation of latent tuberculosis and hepatitis B infection), leukopenia, infusion-related reactions</td>
<td></td>
</tr>
<tr>
<td>Caveats</td>
<td></td>
</tr>
<tr>
<td>General immunosuppression</td>
<td>Modest effect in induction therapy for CD</td>
</tr>
<tr>
<td>Frequent loss of response</td>
<td>No long-term safety data available</td>
</tr>
<tr>
<td>Increased rate of malignancies</td>
<td>Risk of PML infection not ruled out</td>
</tr>
<tr>
<td>Possibly increased rate of malignancies</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CD, Crohn’s disease; FDA, US Food and Drug Administration; IBD, inflammatory bowel disease; PML, progressive multifocal leukoencephalopathy; TNF, tumor necrosis factor.
was first assumed from data of the described clinical trials, case reports of JC (John Cunningham) virus infection with fatal progressive multifocal leukoencephalopathy (PML) after therapy with natalizumab largely restricted its use and damped the early enthusiasm about the potential of leukocyte migration inhibitors.\textsuperscript{37–39} Nonetheless, proof of concept was shown and, as a consequence, newer gut-specific biologics such as vedolizumab were designed.

**Development of vedolizumab for inflammatory bowel disease**

**Pharmacodynamics**

Vedolizumab (MLN0002, MLN02, LDP-02, anti-\( \alpha_4 \beta_7 \)) is a humanized monoclonal immunoglobulin G, antibody targeting \( \alpha_4 \beta_7 \) integrin, which is a potential ligand of VCAM-1 or MAdCAM-1. Pharmacological studies showed that the highest level of vedolizumab binding is to a subset of memory CD4+ cells (including T \(_h\) 17 cells) and eosinophils. Low-to-intermediate-level binding was observed for naïve CD4+ cells, CD8+ cells, B cells, natural killer cells, and basophils. Vedolizumab did not bind to neutrophils, the majority of memory CD4+ lymphocytes, and most monocytes. Importantly, highly specific binding of vedolizumab to \( \alpha_4 \beta_7 \), but not to \( \alpha_4 \beta_1 \) or \( \alpha_5 \beta_7 \), integrins was confirmed by a series of flow cytometry analyses. Interestingly, although \( \alpha_4 \beta_7 \), integrin is a potential ligand for both MAdCAM-1 and VCAM-1, vedolizumab selectively inhibited adhesion of \( \alpha_4 \beta_7 \), integrin-expressing cells to MAdCAM-1 but not to VCAM-1, even at high concentrations.\textsuperscript{40} Taken together, these pharmacological properties of vedolizumab suggest that it has the potential to modulate the adaptive immune system of the gastrointestinal tract without causing the systemic side effects that were reported for natalizumab.

**Pharmacokinetics**

The pharmacokinetic properties of vedolizumab were first assessed in a Phase II dose-ranging study with 46 patients with UC. Infusions of 2 mg/kg, 6 mg/kg, or 10 mg/kg vedolizumab or placebo were administered on day 1, day 15, day 29, and day 85, and evaluations were performed repeatedly through day 253. Maximum serum concentrations and the area under the curve increased proportionally to the administered dose, and serum concentrations declined with a mean half-life of 15–22 days. Maximum saturation of \( \alpha_4 \beta_7 \), integrin on serum lymphocytes was observed at all measurable serum concentrations of vedolizumab.\textsuperscript{41} Pharmacokinetic data from the Phase III clinical trials that are described in detail below suggest a similar profile in patients with UC or CD, with similar serum trough concentrations at week 6 after administration of 300 mg of vedolizumab at week 0 and week 2 and at steady state using application intervals of 4 weeks or 8 weeks. Importantly, a target saturation of >95% was reported for both dosing intervals and independent of CD of UC. Anti-vedolizumab antibodies were detected in 4.1% (CD) and 3.7% (UC) of patients in at least one sample, and rates were reduced in patients with concomitant immunosuppressive therapy.\textsuperscript{42,43}

**Efficacy and safety**

After promising results of a study in cotton-top tamarins with chronic colitis, in which administration of an anti-\( \alpha_4 \beta_7 \), monoclonal antibody reduced colonic inflammation and ameliorated diarrhea,\textsuperscript{44} Feagan et al\textsuperscript{45} tested the efficacy of vedolizumab in a double-blind, controlled trial of vedolizumab in 181 patients with active UC (for an overview of studies with clinically valuable endpoints, Table 2). Patients were randomly assigned to receive an infusion of vedolizumab (0.5 mg/kg or 2.0 mg/kg) or placebo on day 1 and day 29. The primary outcome measure was clinical remission at week 6, defined as an UC clinical score \( \leq 1 \) and a modified Baron endoscopic score \( \leq 1 \), with no evidence of rectal bleeding. Moreover, changes in clinical scores and endoscopic response were evaluated. Clinical remission rates at week 6 significantly differed between patients who received 2.0 mg/kg (32%, \( n=60 \)) or 0.5 mg/kg (33%, \( n=58 \)) of vedolizumab, compared with placebo (14%, \( n=63 \), \( P=0.02 \)). Consistently, endoscopic remission was observed in 28% of patients receiving 0.5 mg/kg and 12% of those receiving 2.0 mg/kg of vedolizumab, compared with 8% of those receiving placebo (\( P=0.007 \)). The prevalence of adverse events was similar in all groups.

In a second double-blind, randomized controlled trial, 185 patients with active CD who were naïve to biologic therapies and had inflammation of the ileum and/or colon were randomized to receive an infusion of vedolizumab (0.5 mg/kg or 2.0 mg/kg) or placebo on day 1 and day 29.\textsuperscript{46} The primary end point was clinical response at week 8, defined as a decrement in the Crohn’s Disease Activity Index (CDAI)\textsuperscript{47} by \( \geq 70 \) points. Additional end points were clinical remission (CDAI \( \leq 150 \)) and CDAI-100 response (decrement in CDAI by \( \geq 100 \) points from baseline). The primary outcome was not met, as clinical response rates were similar in patients who received 2.0 mg/kg (53%; \( n=65 \)) or 0.5 mg/kg of vedolizumab (49%; \( n=62 \)) or placebo (41%; \( n=58 \)). However, rates of clinical remission and CDAI-100 response differed significantly between the 2.0 mg/kg and
<table>
<thead>
<tr>
<th>Study identifier</th>
<th>Condition</th>
<th>N</th>
<th>Dose (interval)</th>
<th>Primary outcome measures</th>
<th>Endpoint met?</th>
</tr>
</thead>
<tbody>
<tr>
<td>n/a</td>
<td>UC</td>
<td>181</td>
<td>0.5 mg/kg, 2.0 mg/kg or PBO (week 0, week 4)</td>
<td>Clinical remission (colitis clinical score ≤1, modified Baron score ≤1, no rectal bleeding) after 6 weeks</td>
<td>Yes&lt;sup&gt;65&lt;/sup&gt;</td>
</tr>
<tr>
<td>NCT00655135</td>
<td>CD</td>
<td>185</td>
<td>0.5 mg/kg, 2.0 mg/kg or PBO (week 0, week 4)</td>
<td>Clinical response (CDAI reduction ≥70 from BL) after 8 weeks</td>
<td>No&lt;sup&gt;66&lt;/sup&gt;</td>
</tr>
<tr>
<td>NCT00783718</td>
<td>UC</td>
<td>895</td>
<td>300 mg or PBO (week 0, week 2, week 6; then 4-week or 8-week intervals for up to 1 year)</td>
<td>1. Clinical response (MCS reduction ≥3 and ≥30% from BL, decrease in the rectal bleeding subscore ≥1 or absolute subscore of 0 or 1) after 6 weeks 1. Yes</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2. Clinical remission (MCS ≤2, no subscore &gt;1) after 52 weeks</td>
<td>2. Yes&lt;sup&gt;62&lt;/sup&gt;</td>
</tr>
<tr>
<td>NCT00783692</td>
<td>CD</td>
<td>1,115</td>
<td>300 mg or PBO (week 0, week 2, week 6; then 4-week or 8-week intervals for up to 1 year)</td>
<td>1. Clinical remission (CDAI ≤150), CDAI-100 response after 6 weeks</td>
<td>1. Yes/No</td>
</tr>
<tr>
<td>(GEMINI II)</td>
<td></td>
<td></td>
<td></td>
<td>2. Clinical remission (CDAI ≤150) after 52 weeks</td>
<td>2. Yes&lt;sup&gt;63&lt;/sup&gt;</td>
</tr>
<tr>
<td>NCT01224171</td>
<td>CD</td>
<td>416</td>
<td>300 mg or PBO (week 0, week 2, week 6)</td>
<td>Clinical remission (CDAI ≤150) in the TNF-α antagonist therapy subpopulation after 6 weeks</td>
<td>No&lt;sup&gt;69&lt;/sup&gt;</td>
</tr>
<tr>
<td>(GEMINI III)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT00790933</td>
<td>CD and UC</td>
<td>2,200 (est)</td>
<td>300 mg (4-week interval for up to 7 years)</td>
<td>Adverse events, serious adverse events, time to major IBD-related events (hospitalizations, surgeries or procedures), improvements in quality of life</td>
<td>Ongoing</td>
</tr>
<tr>
<td>(GEMINI LTS)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02038920</td>
<td>CD</td>
<td>110  (est)</td>
<td>300 mg or PBO (week 0, week 2, week 6; then 8-week interval)</td>
<td>1. CDAI-100 response after 10 weeks</td>
<td>Ongoing</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2. Clinical remission (CDAI ≤150) after 60 weeks</td>
<td></td>
</tr>
<tr>
<td>NCT02039505</td>
<td>UC</td>
<td>278  (est)</td>
<td>300 mg or PBO (week 0, week 2, week 6; then 8-week interval)</td>
<td>1. Clinical response (MCS reduction ≥3 and ≥30% from BL, decrease in the rectal bleeding subscore ≥1 or absolute subscore of 0 or 1) after 10 weeks</td>
<td>Ongoing</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2. Clinical remission (MCS ≤2, no subscore &gt;1) after 60 weeks</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** BL, baseline; CD, Crohn's disease; CDAI, Crohn's Disease Activity Index; CDAI-100, decrement in CDAI score by 100 or more points from baseline; IBD, inflammatory bowel disease; MCS, Mayo Clinic Score; n/a, not available; PBO, placebo; TNF, tumor necrosis factor; UC, ulcerative colitis.
placebo group. Rates of adverse events were again similar in all groups.

Most recently, encouraging results were published from a series of large multicenter, double-blind, randomized controlled trials of vedolizumab in UC and CD patients (Table 2). In the GEMINI I trial, 374 patients with UC were randomized to receive an infusion of 300 mg of vedolizumab or placebo at week 0 and week 2; clinical response (defined as a decrease in the Mayo Clinic Score [MCS] ≥3 points and ≥30% from baseline as well as a decrease in the rectal bleeding subscore of ≥1 or an absolute rectal bleeding subscore of 0 or 1) was evaluated at week 6. An additional cohort (521 patients) received open-label vedolizumab. In a maintenance study, patients who had a response to vedolizumab were randomly assigned to continued therapy with vedolizumab every 8 weeks or 4 weeks or to placebo for up to 52 weeks; rates of clinical remission (MCS ≤2 and no subscore >1) were determined. Rates of clinical response at week 6 were 47.1% in the vedolizumab group versus 25.5% in the placebo group (P<0.001). Moreover, at week 52, clinical remission was seen in 41.8% and 44.8% of patients who received vedolizumab every 8 weeks or 4 weeks, respectively, compared with 15.9% of patients who were switched to placebo (P<0.001). Rates of adverse events were again similar in all groups.

In a similar study of vedolizumab in CD (GEMINI II trial), the results were less clear. While rates of clinical remission (CDAI ≤150) at week 6 differed significantly between patients treated with 300 mg of vedolizumab at week 0 and week 2 (14.5%; n=220) compared with placebo (6.8%; n=148; P=0.02), effects were modest and the other primary endpoint, defined as a CDAI-100 response at week 6, was not met (31.4% versus 25.7%). In the maintenance trial with vedolizumab-responders, clinical remission rates at week 52 were higher in patients assigned to continuous vedolizumab therapy every 8 weeks or 4 weeks (39.0% and 36.4%) than in those who were switched to placebo (21.6%; P<0.001 and P=0.004, respectively). Higher rates of serious adverse events (24.4% versus 15.3%), infections (44.1% versus 40.2%), and serious infections (5.5% versus 3.0%) were observed in the vedolizumab groups compared with placebo.

Comparable results were obtained in the recently published GEMINI III trial, which addressed the efficacy of vedolizumab in patients with moderately to severely active CD and failure or intolerance to prior anti-TNF therapy, a subgroup that reflects a frequent setting in everyday clinical practice. Patients were randomized to receive 300 mg of intravenous vedolizumab or placebo at week 0, week 2, and week 6. The primary endpoint, which was defined as clinical remission (CDAI ≤150) at week 6 in the subgroup of patients with prior anti-TNF failure, was not met (15.2% versus 12.1%, P=0.433). However, exploratory analyses of secondary endpoints showed higher rates of clinical remission at week 10 and higher rates of CDAI-100 response at week 6 and week 10 in the anti-TNF failure subgroup when treated with vedolizumab compared with placebo. Rates of adverse events were similar in all groups.

In summary, these studies provide strong evidence that vedolizumab is effective as an induction and maintenance therapy for UC. Vedolizumab also showed promise in non-bionaive CD patients. The effects of continuous vedolizumab therapy for UC and CD patients who showed an initial nonresponse was addressed in an unpublished analysis that was presented at the Digestive Disease Week 2014. Interestingly, data suggest that continued application of vedolizumab in initial nonresponders can lead to additional effects on clinical response and remission rates at later time points. Hence, the actual clinical benefit of vedolizumab might be underestimated in the GEMINI trials due to a delayed response.

The long-term safety of vedolizumab is currently assessed in the open-label GEMINI LTS trial (NCT00790933) with pooled data from the Phase II or Phase III trials and new patients who were naïve to vedolizumab. In an early pooled safety analysis of the GEMINI I and II trials, rates of adverse events and serious adverse events were higher in the vedolizumab group when compared with placebo. However, the overall rate of adverse events adjusted for patient-years was higher in the placebo group. The most frequently reported adverse events were nasopharyngitis (13%), headache (12%), arthralgia (12%), nausea (9%), and pyrexia (9%), which suggests an acceptable safety profile. Moreover, clinically important infusion reactions were infrequent, and no case of anaphylaxis was observed in the GEMINI I and II trials, which allows the application of vedolizumab in clinical practice without premedications, ie, glucocorticoids, which are frequently used together with anti-TNF therapy.

The European Medicines Agency and FDA approved vedolizumab (trade name Entyvio®; Takeda Pharmaceuticals) for the treatment of adult patients with moderate to severe UC or moderate to severe CD who showed inadequate response to one or more standard therapies.

**Clinical status of vedolizumab and future directions**

More than 20 years after the identification of the proteins that are involved in leukocyte homing to the gastrointestinal
tract, vedolizumab is now available as the first approved member of gut-specific leukocyte migration inhibitors for the treatment of IBD. In the past decade, TNF inhibitors have become an established therapy in severe UC and CD and are more and more used as a first-line medication, especially in fistulizing CD (Table 1). However, anti-TNF therapy has to be discontinued in many patients due to secondary lack of response or adverse effects such as infections or allergic reactions. The results of the large clinical trials presented above raise hope that vedolizumab could become a new drug option for these patients and prevent or delay surgical intervention in some cases.

Apart from its use as a “salvage therapy,” vedolizumab may assume another role in patients who have contraindications to current immunomodulators or anti-TNF biologics. The current label covers its use when one or more standard therapies (which includes corticoids) have failed, so theoretically, it could be used as a first-line biologic therapy. Interestingly, results of a recent network meta-analysis suggest similar efficacy and safety of vedolizumab and anti-TNF therapy (ie, adalimumab, infliximab, or golimumab) for induction and maintenance therapy in bionaïve patients with moderately to severely active UC, which supports its use as an alternative first-line biologic. However, to clearly define the role of vedolizumab in the spectrum of currently available biologics, comparison trials are urgently needed.

An important aspect that needs consideration is the difference in observed efficacy of vedolizumab induction therapy in UC and CD: whereas data in UC are convincing, only a modest effect was observed in patients with CD. Sandborn et al argue that the severity of disease in the study population could be a potential confounder. Indeed, the high rates of prior surgery (42%) and failure of at least one TNF antagonist (approximately 50%) suggest a CD population with refractory disease. Interestingly, the rate of prior failure of anti-TNF-therapy in the GEMINI I population was lower (approximately 40%), which may underlie the difference in observed efficacy. In accordance with this hypothesis, subgroup analyses in both the GEMINI II and GEMINI III trials show a trend towards higher rates of CDAI-100 response and clinical remission in bionaïve patients. In addition to confounding, a delayed effect of vedolizumab in CD, possibly due to the transmural nature of disease, may explain the modest results at week 6. The marked increase of remission rates between week 6 and week 10 in the GEMINI III trial and the additional effects of continued therapy in initial nonresponders strongly support this assumption and have important implications for the evaluation of response in clinical practice. However, more trials in different subgroups and with longer induction protocols are necessary to determine the actual effect of vedolizumab in CD.

Another investigation-worthy subject remains the effect of vedolizumab on extraintestinal manifestations of IBD, especially as it could be limited due to the gut-specificity of the drug. More research is needed to address the efficacy of vedolizumab in patients with extraintestinal manifestations of IBD.

The pooled safety analysis of the GEMINI I and GEMINI II trials suggests that vedolizumab has a safety profile that is comparable with or even better than that of anti-TNF therapy. However, cautious observation of long-term effects is necessary, especially with respect to opportunistic infections such as PML. Theoretically, the gut-specific design of vedolizumab should not impair binding of \( \alpha_4\beta_7 \) integrin to VCAM-1, which is critical for the migration of lymphocytes to the central nervous system. In the more than 3,000 patients who have received vedolizumab as of today, no cases of PML have been reported. However, PML infection is a rare event, with an estimated risk of 0.5–1.4 per 1,000 patients who are treated with natalizumab for 1–24 months after prior immunosuppressant therapy; thus, postmarketing risk-management strategies are justified. Moreover, four cases of malignant neoplasms were reported in the GEMINI II study, suggesting that careful monitoring of the occurrence of cancer as a potential adverse event of long-term therapy is necessary.

Apart from vedolizumab, other molecules that target leukocyte migration to the gut are currently investigated in Phase II and Phase III clinical trials. Etrolizumab (rhuMAB-\( \beta_7 \), anti-\( \beta_7 \); Hoffmann–La Roche), a humanized monoclonal antibody that targets the \( \beta_7 \) subunit of both the \( \alpha_4\beta_7 \) and \( \alpha_7\beta_7 \) integrin heterodimers, was recently shown to be more efficient than placebo as an induction therapy for UC, and its anti-\( \alpha_4\beta_7 \) activity could be favorable as the \( \alpha_4\beta_7 \) integrin–E-cadherin interaction is believed to promote lymphocyte retention. Other biologics that target the \( \alpha_4\beta_7 \) integrin–MAdCAM-1 interaction are PF-00547659 (anti-MAdCAM; Pfizer) and AMG 181 (anti-\( \alpha_7\beta_7 \); Amgen). Clinical trials need to address whether their efficacy and safety are comparable to that of vedolizumab, and eventually head-to-head studies will be necessary to integrate these new agents into treatment algorithms, especially with regard to the choice of the initial biologic drug.

**Conclusion**

The gut-specific inhibition of lymphocyte migration with vedolizumab seems to be an effective and safe new treatment
option for patients with IBD, although many issues still have to be addressed in additional clinical trials, it will be interesting to see if vedolizumab will change clinical practice and how it performs against established drugs and other new treatment strategies.

Disclosure

Daniel C Baumgart has served as a speaker or paid scientific consultant for Takeda, Genentech, Roche and Pfizer, that are developing anti-adhesion therapies. All of his activities and contracts are in conformity with the “FSA-Kodex Fachkreise” (voluntary self-monitoring code for expert consultants to the pharmaceutical industry), have been checked by the legal Department of Charité - Universitätsmedizin Berlin, and have been approved by the directorate of the Faculty of Medicine Charité - Universitätsmedizin Berlin. Niklas Krupa reports no conflicts of interest in this work.

References


